Preclinical studies have shown that lenvatinib, a multiple receptor tyrosine kinase inhibitor, has immunomodulatory activity which improves T-cell activation and reduces tumor-associated macrophages, resulting in enhanced antitumor activity when combined with anti-PD-1 antibody (Kato et al., 2019, Kimura et al., 2018, Tran et al., 2023). The gene discussed is NTRK1; the disease is neoplasm.